PRESS RELEASE Dr Nicco's new Chief Operating Officer (COO) position will give her a broader mandate at BioSenic, where she is currently responsible for R&D programs. Mont-Saint-Guibert, Belgium, January 10, 2024, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, and its subsidiary Medsenic SAS, today announces the promotion of Dr Carole Nicco to Chief Operating Officer (COO) in ad
Related Keywords
France , Paris , France General , Walloon Region , Waals Gewest , Belgium , Mont Saint Guibert , French , Neil Hunter Michelle Boxall , Carole Nicco , Ghislaine Gasparetto , University Paris Cit , International Media Enquiries , Ib Communications , Chief Operating Officer , Euronext Brussels , Chief Scientific Officer , Graft Versus Host Disease , Louvain La Neuve Science Park , Mesenchymal Stromal Cells , Chief Executive , Media Enquiries , French Investor Enquiries , Chief Executive Officer , Chicco , Strategic Decisions , Strategic Development , Cell Therapy , Inflammatory Diseases ,
comparemela.com © 2020. All Rights Reserved.